Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 1;33(1):50-58.
doi: 10.1097/MOU.0000000000001045. Epub 2022 Oct 21.

Treatment of adrenocortical carcinoma: oncological and endocrine outcomes

Stephan Brönimann  1 , Nathalie Garstka, Mesut Remzi
Affiliations
Review

Treatment of adrenocortical carcinoma: oncological and endocrine outcomes

Stephan Brönimann et al. Curr Opin Urol. .

Abstract

Purpose of review: Adrenocortical carcinoma (ACC) is a rare, aggressive disease with a paucity of data and great variability between published studies regarding its treatment. This review provides information on current clinical management and oncological and endocrine outcomes.

Recent findings: Complete surgical resection is the only potentially curative treatment for adrenocortical carcinoma (ACC). Adjuvant mitotane treatment is recommended in patients with favourable/intermediate prognosis. As part of the endocrine follow-up, steroid hormones and thyroid hormones may be decreased or increased and may need to be substituted or suppressed. Recurrences are common. If the disease-free interval is more than 12 months, surgery is a treatment if complete resection is feasible. In advanced/metastatic ACC patients, the prognosis is poor. Mitotane monotherapy is only appropriate for patients with low tumour burden and indolent disease. Patients with unfavourable prognosis should be treated with aggressive cytotoxic therapy. Patients requiring third-line treatment should be considered for clinical trials. Immunotherapy and targeted therapy are currently being investigated, but have so far yielded only unsatisfactory results.

Summary: There is scarce evidence for the treatment of ACC, which often complicates clinical decision-making. Patients who progress on EDP-M should be treated in clinical trials.

PubMed Disclaimer

References

    1. Park HS, Roman SA, Sosa JA. Outcomes from 3144 adrenalectomies in the United States: which matters more, surgeon volume or specialty? Arch Surg 2009; 144:1060–1067.
    1. Villar JM, Moreno P, Ortega J, et al. Results of adrenal surgery. Data of a Spanish National Survey. Langenbeck's Arch Surg 2010; 395:837–843.
    1. Lindeman B, Hashimoto DA, Bababekov YJ, et al. Fifteen years of adrenalectomies: impact of specialty training and operative volume. Surgery 2018; 163:150–156.
    1. Palazzo F, Dickinson A, Phillips B, et al. Adrenal surgery in England: better outcomes in high-volume practices. Clin Endocrinol (Oxf) 2016; 85:17–20.
    1. Gaujoux S, Mihai R. European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma. Br J Surg 2017; 104:358–376.